TNYA · Tenaya Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $68.61M | $86.74M | $98.04M | $94.54M | $31.10M |
| SG&A | $24.72M | $29.21M | $33.16M | $31.08M | $7.81M |
| Total Operating Expenses | $93.33M | $115.95M | $131.19M | $125.62M | $38.91M |
| D&A | $8.44M | $8.47M | $8.69M | $6.47M | $2.48M |
| Operating Income | ($93.33M) | ($115.95M) | ($131.19M) | ($125.62M) | ($38.91M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($90.60M) | ($111.13M) | ($124.08M) | ($123.67M) | ($38.40M) |
| EPS - Basic | ($0.59) | ($1.31) | ($1.68) | ($4.10) | - |
| EPS - Diluted | ($0.59) | ($1.31) | ($1.68) | ($4.10) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $100.55M | $4.32M | $45.68M | $95.27M | $38.13M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $3.58M | $5.16M | $5.63M | $9.58M | $10.72M |
| Current Assets | $105.59M | $67.38M | $111.58M | $193.75M | $255.36M |
| Total Assets | $146.92M | $119.94M | $170.51M | $278.94M | $314.19M |
| Current Liabilities | $15.44M | $15.97M | $22.73M | $24.25M | $21.77M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $23.66M | $27.09M | $31.09M | $35.57M | $35.66M |
| Stockholders' Equity | $123.27M | $92.85M | $139.42M | $243.38M | $278.53M |
| Retained Earnings | ($605.01M) | ($514.41M) | ($403.28M) | ($279.20M) | ($155.53M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($68.26M) | ($90.50M) | ($102.07M) | ($104.42M) | ($35.45M) |
| Investing Cash Flow | $56.08M | $1.13M | $48.72M | $83.65M | ($7.01M) |
| Financing Cash Flow | $108.41M | $47.75M | $4.05M | $77.77M | $147.27M |
| CapEx | $618.0K | $1.02M | $1.24M | $20.63M | $9.76M |
| Free Cash Flow | ($68.88M) | ($91.53M) | ($103.31M) | ($125.05M) | ($45.21M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.76 | 0.82 | 0.83 | 1.01 | 1.18 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -61.7% | -92.7% | -72.8% | -44.3% | -12.2% |
| Return on equity | -73.5% | -119.7% | -89.0% | -50.8% | -13.8% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 6.84 | 4.22 | 4.91 | 7.99 | 11.73 |
| Quick ratio | 6.84 | 4.22 | 4.91 | 7.99 | 11.73 |
| Cash ratio | 6.51 | 0.27 | 2.01 | 3.93 | 1.75 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.19 | 1.29 | 1.22 | 1.15 | 1.13 |
| Liabilities / Assets | 0.16 | 0.23 | 0.18 | 0.13 | 0.11 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 0.9x | 1.3x | 1.7x | 0.1x | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 19.5% | 11.6% | -4.4% | -222.8% | - |
| Net income growth (YoY) | 18.5% | 10.4% | -0.3% | -222.1% | - |
| EPS growth (YoY) | 55.0% | 22.0% | 59.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 24.7% | 11.4% | 17.4% | -176.6% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 32.8% | -33.4% | -42.7% | -12.6% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Tenaya Therapeutics against the 5 most active filers in the same SIC group.